News
JNJ
144.47
+0.62%
0.89
Weekly Report: what happened at JNJ last week (1216-1220)?
Weekly Report · 5h ago
Hartford Balanced Income Fund Q3 2024 Commentary
Seeking Alpha · 22h ago
If I Had To Invest $100,000 In A Dividend Growth Portfolio Right Now, Here's What I Would Buy
Seeking Alpha · 2d ago
RxSight cut to hold at Stifel on competition concerns
Seeking Alpha · 2d ago
RxSight downgraded to Hold from Buy at Stifel
TipRanks · 3d ago
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
Benzinga · 3d ago
Can Dow Jones ETF Reverse From the Worst Losing Streak in 50 Years?
NASDAQ · 3d ago
Notable ETF Inflow Detected - IWD, WMT, JNJ, PG
NASDAQ · 3d ago
Johnson & Johnson: Dividend Legend At A Discount
Seeking Alpha · 3d ago
Guru Fundamental Report for JNJ
NASDAQ · 4d ago
RBC Capital Keeps Their Buy Rating on Johnson & Johnson (JNJ)
TipRanks · 4d ago
What's Next For Pfizer Stock?
NASDAQ · 4d ago
Of 63 Fortune500 Industry Leaders, 57 Pay Dividends, 38 Test 'Safer' & 1 Is Ideal To Buy
Seeking Alpha · 4d ago
Dow’s drop: How blue-chips have fared during index’s peak turned worst-run in decades
Seeking Alpha · 4d ago
Least shorted S&P 500 stocks in November
Seeking Alpha · 4d ago
Dow on a Record Losing Streak: Should You Buy its ETF?
NASDAQ · 4d ago
Trump Trade: Analyst says Trump win ‘not as positive as you’d think’ for Tesla
TipRanks · 4d ago
FDA approves Celltrion's biosimilar of J&J's Stelara
Seeking Alpha · 4d ago
PBMs took payments from manufacturers to allow free flow of opioids, NYT reports
TipRanks · 4d ago
My Dividend Stock Portfolio: New November Dividend Record - 97 Holdings With 18 Buys
Seeking Alpha · 5d ago
More
Webull provides a variety of real-time JNJ stock news. You can receive the latest news about Johnson & Johnson through multiple platforms. This information may help you make smarter investment decisions.
About JNJ
Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. It operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, interventional solutions, cardiovascular intervention, and vision fields. The MedTech segment also offers a commercially available intravascular lithotripsy (IVL) platform for coronary artery disease (CAD) and peripheral artery disease (PAD).